Summit Therapeutics is trading at $14.29 (-4.61%) in pre-market after its second-quarter earnings update revealed a wider loss and no revenue for the period.
- The company highlighted a strengthened balance sheet and a strategic shift in focus toward the upcoming ivonescimab PDUFA date.
- Despite the capital-raising update, the report failed to show a near-term commercial boost, weighing on investor sentiment.
- Broader market pressure, including tech sector weakness and tariff-related headlines, is contributing to the cautious trading environment.